Publication of high-quality biomedical and health services research has an important role to play in informing and shaping health policy. Not only does research assist in examining issues and finding solutions to vexing problems, but published research provides a means to educate stakeholders who influence legislation, regulation, and policy decisions.Citation1,2 Certainly, health services research can guide the provision of care in many domains: (1) access, (2) organization, (3) financing, (4) reimbursement, (5) costs, (6) quality, (7) special populations, and (8) ethical and legal issues.Citation1 Increasingly, research is focused on examining the clinical and public health aspects of certain policies. In the addiction field, this could apply to such topics as the impact of the Parity Laws and Affordable Care Act on access to and quality of addiction treatmentCitation3–6 and the impact of buprenorphine regulations and policies.Citation7–10 For lack of a better term, research that directly examines the influence of policy or regulations on clinical care can be defined as applied regulation and policy examination and research (ARPER). Along with research that informs stakeholders about the current evidence-based approaches to addiction-related care or public health, ARPER has an important role to play in addiction-related care and public health.
Scholars who examine addiction-related ARPER are sorely needed. Like translational, health services, and implementation research before it, addiction-related ARPER is a new field. At Substance Abuse journal we are actively seeking to publish more ARPER.Citation11 We believe it is essential to examine contemplated, ongoing, or completed policies and regulations that influence addiction treatment in order to truly impact patient care. We are also committed to publishing this work quickly, after sound peer review, so that this research can inform current or future policy debates.
The Association for Medical Education and Research in Substance Abuse (AMERSA; www.amersa.org) is an organization with a mission to “improve health and well-being through interdisciplinary leadership in substance use education, research, clinical care, and policy.” One of AMERSA's stated goals is to “provide an active forum and community for discussion and debate of health policy topics related to substance use.” ARPER and policy advocacy are essential parts of the mission and goals. In that vein, in November 2015, AMERSA's 39th annual meeting in Washington, DC, focused on the theme “Integrating Policy and Research Into Teaching and Practice.” Conference Chairs, Paula J. Lum, MD, MPH, and Gerald Cochran, PhD, MSW, offered a wealth of addiction policy-related content via plenary discussions on such topics as (1) drug policies implication on the rights, health, and well-being of pregnant women and their children; (2) policy and implementation issues of naloxone rescue kits to confront opioid overdoses; and (3) a debate regarding substance use confidentiality laws. Additionally, the journal contributed to this policy theme during the distribution of annual awards at the AMERSA conference. We recognized Christian Hopfer's, MD, article, “Implications of Marijuana Legalization for Adolescent Substance Use,” as Substance Abuse journal's 2015 Most Downloaded Manuscript and selected Jessica J. Black's, MD, article, “Mechanisms of Change in Adolescent Substance Use Treatment: How Does Treatment Work?,” for Substance Abuse journal's Best Manuscript of 2015.Citation12,13
Many of the scientific posters, presentations, and workshops at the AMERSA conference could influence policy decisions and were directly ARPER-related work (see Supplemental Material). For example, Sion Kim Harris, PhD, and colleagues presented work regarding medical marijuana diversion in two clinical populations of youth and the early trends in this use after legalization, and Daniel P. Alford, MD, MPH, and colleagues presented an assessment of an opioid risk evaluation and medication strategy continuing education program aimed at improving provider opioid prescribing practices. We at the journal advocate for more attention at future AMERSA conferences regarding research that may influence policy and ARPER.
Finally, the quality and impact of ARPER and more traditional forms of research rely substantially on the contributions of peer reviewers. As always, we are grateful for the 285 peer reviewers who voluntarily provided over 350 external reviews for our journal in calendar year 2015. Why should anyone do a peer review? We certainly hope that reviewers believe they are contributing to the advancement of science, that their input makes their peers' work better, and that reviewing other scholars' work makes their own work stronger. Interestingly, a perception that finding external peer reviewers for a particular article is difficult has not come to fruition during my tenure as an Editor-in-Chief. Perhaps we in the addiction field, as opposed to scholars in other fields, are more willing to advance the field as a whole through critical evaluation of each other's research. Below, we list all the peer reviewers who reviewed for the journal in 2015. All of them contributed sound, thoughtful reviews. For the last two years, Substance Abuse journal has awarded its “Best Peer Review” of the year, and the 2015 award was presented to Jeffrey Baxter, MD, from the University of Massachusetts. This award has become more competitive as the quality of external peer review has risen each year. The journal is deeply indebted to these external peer reviewers for their ongoing scholarship and contribution to the addiction field.
In sum, Substance Abuse journal is pleased to further the mission of AMERSA via support of each step of the research process, beginning with solicitation of articles in underrepresented areas of research, such as ARPER, to publication of abstracts reporting emerging findings, to thorough peer review of full articles, and finally, the publication and promotion of high-quality work in order to improve patient care and inform addiction policy.
SUBSTANCE ABUSE ASSOCIATE EDITORS 2015
Ingrid A. Binswanger
Lauren Matukaitis Broyles
Alan A. Cavaiola
Babalola Faseru
Deborah S. Finnell
Marianne Pugtach
SUBSTANCE ABUSE PEER REVIEWERS 2015
Aase, Darrin M.
Acosta, Joie D.
Acquavita, Shauna P.
Albizu-Garcia, Carmen E.
Andrade, André Luiz Monezi
Asadi, Soraya
Ashrafioun, Lisham
Bajaj, Vikrant
Bakken, Nicholas
Balan, Yener A.
Bamberger, Joshua D.
Banta-Green, Caleb
Barros, Víviam
Barry, Adam E.
Barry, Declan T.
Barth, Kelly S.
Baxter, Jeffrey
Beatty, Jessica R.
Becker, Sara J.
Bennett, Alex S.
Berends, Lynda
BigFoot, Dolores Subia
Bird, Sheila
Blosnich, John
Borsari, Brian
Bramoweth, Adam
Bray, James
Bride, Brian
Broderick, Kerry
Bronars, Carrie
Browne, Teri
Burge, Sandra K.
Buscemi, Joanna
Buxton, Jane
Buykx, Penny
Cacciola, John
Capron, Daniel
Carlson, Robert G.
Castellanos, Daniel
Castro, Yessenia
Cernovsky, Zack
Childers, Julie
Choi, Seung Hee
Christopher, Melissa
Clemence, A. Jill
Coffin, Phillip O.
Collins, Susan E.
Copeland, Jan
Cottencin, Olivier
Coulton, Simon
Coviello, Donna M.
Crandall, Cameron
Croff, Julie
Daigre, Constanza
Darke, Shane
Dauria, Emily
Davies, Susan
Davis, Alan K.
Davis, Corey
Dawes, Michael Anthony
de Dios, Marcel
Dekker, Anthony H.
DeLay, Dawn
Deutsch, Arielle R.
DiNardo, Monica
DiNitto, Diana M.
Dole, Ernest
Doorley, Sara L.
Earleywine, Mitch
Eckstrand, Kristen
Edens, Ellen
El-Setouhy, Maged
Enterman, John
Erdem, Gizem
Escribano, Abel Baquero
Espelt, Albert
Evren, Cuneyt
Famili, Pouran
Farsalinos, Konstantinos E.
Feingold, Daniel
Feinstein, Anthony
Feldman, Jonathan
Fiellin, David A.
Fingerhood, Michael
Fischer, Gabriele
Fogger, Susanne
Ford, James H., II
Ford, Jason A.
Fox, Aaron D.
Frank, Joseph W.
Gandhi, Devang
Garnick, Deborah W.
Gassman, Ruth
Gates, Peter
Gaume, Jacques
Gjersing, Linn
Goodwin, Andrew
Gordon, Joanne M.
Grande, Lucinda
Grassi, Maria Caterina
Green, Traci
Gunderson, Erik
Hache, Guillaume
Hagger-Johnson, Gareth
Hahm, Hyeouk “Chris”
Harris, Kari
Harrison, Craig
Hausmann, Leslie R. M.
Hawkins, Eric
Hayashi, Kanna
Hennessy, Grace
Hohman, Melinda
Holdsworth, Emma
Holttum, Jessica
Hopfer, Christian
Hyatt-Burkhart, Debra
Isenhart, Carl
Jansen, Karl
Jason, Leonard A.
Jefee-Bahloul, Hussam
Johnson, J. Aaron
Johnson, Julie
Johnson, Matthew W.
Jones, Hendrée E.
Jones, Jermaine
Joordens, Chantele
Kaltenbach, Karol
Kalu, Nnenna
Kaucher, Kevin A.
Keast, Shellie L.
Kelly, Len
Kinahan, James
Kingsbury, Mila
Koester, Stephen
Komaromy, Miriam
Korthuis, Todd
Kotlyar, Michael
Kowalchuk, Alicia Ann
Kraemer, Kevin L.
Kranzler, Henry R.
Krull, Ivy
Krupitsky, Evgeny
Kulchak Rahm, Alanna
Lackner, Nina
Larner, A. J.
Lasebikan, Victor Olufolahan
Le Boisselier, Reynald
Lee, Joshua
Leglise, Yves
Lembke, Anna
Lewis, Eleanor T.
Logemann, H. N. Alexander
Loscalzo, Emily
Luis, Margarita
Macgowan, Mark
Magidson, Jessica F.
Majer, John M.
Malouff, John M.
Mannelli, Paolo
Marcus, Marianne T.
Martel, Marc O.
Mason, W. Alex
Matheson, Catriona
Maxwell, Jane C.
McGinnis, Kathleen A.
McHugh, R. Kathryn
McLeish, Alison C.
McNicholas, Laura
Merlo, Lisa J.
Merrill, Joseph O.
Metcalf, Mary P.
Miller, Bryan Lee
Milloy, M.-J.
Mitchell, Ann
Mitchell, Mack
Mitchell, Michael
Morasco, Benjamin
Moreno, Megan
Naegle, Madeline A.
Nahvi, Shadi
Nelson, Tobin
Neumann, Anne M.
Newsom, Andrew
Nielsen, Suzanne
Nordmann, Sandra
Nosyk, Bohdan
Novick, David M.
O'Brien, Charles
O'Connor, Richard J.
O'Conor, Katie J.
Oliva, Elizabeth
Ondersma, Steven J.
Osborne, Victoria
Ostacher, Michael J.
Padhy, Susanta
Padwa, Howard
Palamar, Joseph J.
Park, Tae Woo
Pavarin, Raimondo Maria
Pick, Chagi
Pinto, Rogério M.
Plebani, Jennifer
Preston, Kenzie
Quaglio, Gianluca
Quinn, Catherine
Quraishi, Rizwana
Radfar, Seyed Ramin
Ramaswamy, Megha
Ray, Bradley
Ren, Yanfang
Renner, John
Robinson, Jason D.
Robinson-Papp, Jessica
Rogers, Ralph
Rogowska, Aleksandra
Roose, Robert
Rose, Gail L.
Rotrosen, John
Saba, Shaddy K.
Samuel, Edith
Sanchez, Michael
Santaella, Julian
Sara, Grant
Sargento, Paulo
Sasson, Nicholas J.
Satre, Derek
Satterfield, Jason M.
Savage, Christine
Schrager, Justin
Schram, Patricia Cintra Franco
Schreiner, Amy
Schwartz, Robert P.
Schwinn, Traci M.
Scott, Denise
Shahrir, Shahida
Shariat, Ardalan
Sharp, Daryl
Shiffman, Saul
Shin, Sonya S.
Shrier, Lydia A.
Smith, Douglas
Sox-Harris, Alex
Starrels, Joanna
Stein, Bradley
Stein, Michael
Steinhardt, Sarah J.
Stephenson, Rolena
Sterling, Stacy
Stern, Marc F.
Streltzer, Jon
Strobbe, Stephen
Suffoletto, Brian
Svikis, Dace S.
Swiggart, William
Teruya, Cheryl
Thomas, Janet
Thompson, Megan E.
Tofighi, Babak
Trigg, Bruce G.
Tzilos, Golfo
Urada, Darren
Usdan, Stuart L.
Vertino, Kathleen A.
Wakeman, Sarah
Wallace, Lorraine
Walsh, Sharon L.
Walton, Maureen
Watkins, Katherine
Webster, Lynn
Welle-Strand, Gabrielle K.
Whitley, Susan
Wilder, Christine M.
Williams, Ronald D., Jr.
Witbrodt, Jane
Wolff, Nancy
Wood, Camille
Wood, D. M.
Wooten, Nikki R.
Wray, Laura O.
Yellowlees, Peter M.
Yong, Hua-Hie
Zacny, James P.
Zhai, Zu Wei
Zhou, Wenhua
Supplemental material
This article contains supplemental material that can be accessed on the publisher's website.
WSUB-2016-2550_AMERSA_Abstracts.docx
Download MS Word (219.5 KB)Acknowledgments
The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the University of Pittsburgh, the Department of Veterans Affairs, or the United States government. The author declares that he has no conflicts of interest.
References
- Longest BB. Health Policymaking in the United States. 2nd ed. Chicago, IL: Health Administration Press; 1998.
- Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–1632.
- McLellan AT, Woodworth AM. The affordable care act and treatment for “substance use disorders”: Implications of ending segregated behavioral healthcare. J Subst Abuse Treat. 2014;46:541–545.
- Capoccia VA, Grazier KL, Toal C, Ford JH 2nd, Gustafson DH. Massachusetts's experience suggests coverage alone is insufficient to increase addiction disorders treatment. Health Aff (Millwood). 2012;31:1000–1008.
- Woody GE. Progress in addiction treatment: From one-size-fits-all to medications and treatment matching. Subst Abus. 2014;35:110–113.
- Roll JM, Kennedy J, Tran M, Howell D. Disparities in unmet need for mental health services in the United States, 1997–2010. Psychiatr Serv. 2013;64:80–82.
- Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: The influence of state policies. J Subst Abuse Treat. 2015;48:104–111.
- Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Subst Abus. 2016;37:63–69.
- Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv. Res. 2014;49:1964–1979.
- Baxter JD, Clark RE, Samnaliev M, Aweh G, O'Connell E. Adherence to buprenorphine treatment guidelines in a Medicaid program. Subst Abus. 2015;36:174–182.
- Gordon AJ. Substance Abuse journal: New beginnings. Subst Abus. 2013;34:339–341.
- Hopfer C. Implications of marijuana legalization for adolescent substance use. Subst Abus. 2014;35:331–335.
- Black JJ, Chung T. Mechanisms of change in adolescent substance use treatment: How does treatment work? Subst Abus. 2014;35:344–351.